ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the ... Rituximab; SLL: Small lymphocytic lymphoma; VOD: Veno-occlusive disease. Y-A Chu and W Polson are employees ...

A Phase I study included 13 patients with a variety of relapsed B-cell NHL (five follicular, three mantle cell, three DLBCL, two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]).

Colleagues have previously demonstrated the safety and efficacy of an oral chemotherapy regimen for aggressive non-Hodgkin's lymphoma in East Africa ... were eligible if their CD4 + T-cell count was ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...

UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

This protein drives cell growth in cancers that are ... drugs in people who have relapsed or refractory non-Hodgkin's lymphoma. Centrinone B was the starting point for Repare Therapeutics ...

“Three days later, my doctors called me back and they said, ‘We wish we had better news for you, but you have non-Hodgkin’s lymphoma and it’s called B cell and it’s very aggressive ...

Ascentage Pharma Group International’s AAPG share price has dipped by 6.94%, which has investors questioning if this is right ...